Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer, April 2022

Free Subscription


Abstracts

Retrieve all available abstracts of the following 318 articles:
HTML format


 

Single Articles

  1. XU T, Junge JA, Delfarah A, Lu YT, et al
    Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time.
    Sci Rep. 2022;12:5518.
    PubMed    
    Abstract available

  2. MOISOIU T, Dragomir MP, Iancu SD, Schallenberg S, et al
    Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer.
    Mol Med. 2022;28:39.
    PubMed    
    Abstract available

  3. WU X, Cao W, Lu C, Zuo L, et al
    circ3323 Motivates Host Gene to Promote the Aggressiveness of Bladder Cancer.
    Biochem Genet. 2022 Apr 1. pii: 10.1007/s10528-022-10210.
    PubMed    
    Abstract available

  4. YE L, Chen Y, Xu H, Xie H, et al
    Biparametric magnetic resonance imaging assessment for detection of muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Eur Radiol. 2022 Apr 1. pii: 10.1007/s00330-022-08696.
    PubMed    
    Abstract available

  5. TEOH JY, Kamat AM, Black PC, Grivas P, et al
    Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.
    Nat Rev Urol. 2022 Mar 31. pii: 10.1038/s41585-022-00578.
    PubMed    
    Abstract available

  6. ZHANG Y, Huo F, Cao Q, Jia R, et al
    FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer.
    J Immunother Cancer. 2022;10.
    PubMed    
    Abstract available

  7. YUAN S, Zhai Y, Tao T, Zhang X, et al
    Conflicting Roles of ZFP36L1 in Regulating the Progression of Muscle Invasive Bladder Cancer.
    Front Mol Biosci. 2022;9:687786.
    PubMed    
    Abstract available

  8. ASTROM LM, Behrens CP, Calmels L, Sjostrom D, et al
    Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: initial experience and dosimetric benefits.
    Radiother Oncol. 2022 Mar 28. pii: S0167-8140(22)00152.
    PubMed    
    Abstract available

  9. ZHANG X, Xiong H, Zhao Y, Lin S, et al
    Circular RNA LONP2 regulates proliferation, invasion, and apoptosis of bladder cancer cells by sponging microRNA-584-5p.
    Bioengineered. 2022;13:8823-8835.
    PubMed    
    Abstract available

  10. GRUNEWALD CM, Feldmeier V, Supprian T, Albers P, et al
    Cognitive function in patients undergoing cystectomy for bladder cancer - results from a prospective observational study.
    Ther Adv Urol. 2022;14:17562872221087660.
    PubMed    
    Abstract available

  11. GUALLAR-GARRIDO S, Campo-Perez V, Perez-Trujillo M, Cabrera C, et al
    Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-gamma/IL-17 release in bladder cancer treatment.
    Oncoimmunology. 2022;11:2051845.
    PubMed    
    Abstract available

  12. KITAMURA K, Isotani S, Muto S, Horie S, et al
    Efficacy of pembrolizumab in a rare type of bladder cancer arising 25 years after augmentation cystoplasty.
    BMJ Case Rep. 2022;15.
    PubMed    
    Abstract available

  13. THANGAVELU M, Ismail A, Zakaria A, Elmansy H, et al
    Aristolochic acid: What urologists should know.
    Arch Ital Urol Androl. 2022;94:123-125.
    PubMed    
    Abstract available

  14. MEHRNOUSH V, Keramati S, Ismail A, Shabana W, et al
    Adverse pathological outcomes of patients with de novo muscle invasive bladder cancer in Northern Ontario.
    Arch Ital Urol Androl. 2022;94:41-45.
    PubMed    
    Abstract available

  15. DURSUN F, Elshabrawy A, Wang H, Wu S, et al
    Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy.
    Urol Oncol. 2022 Mar 26. pii: S1078-1439(22)00039.
    PubMed    
    Abstract available

  16. LIU J, Zhu X, Yu L, Mao M, et al
    Discovery of novel sulphonamide hybrids that inhibit LSD1 against bladder cancer cells.
    J Enzyme Inhib Med Chem. 2022;37:866-875.
    PubMed    
    Abstract available

  17. ZHOU W, He L, Dai Y, Zhang Y, et al
    MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer.
    Exp Ther Med. 2022;23:312.
    PubMed    
    Abstract available

  18. TRAN TML, Abdelrahman H, Tran C, Abraham R, et al
    A Curious Case of Hypercalcemia.
    R I Med J (2013). 2022;105:39-41.
    PubMed    
    Abstract available

  19. NOVRUZOV E, Dendl K, Ndlovu H, Choyke PL, et al
    Head-to-head Intra-individual Comparison of [(68)Ga]-FAPI and [(18)F]-FDG PET/CT in Patients with Bladder Cancer.
    Mol Imaging Biol. 2022 Mar 29. pii: 10.1007/s11307-022-01715.
    PubMed    
    Abstract available

  20. VALDERRAMA BP, Gonzalez-Del-Alba A, Morales-Barrera R, Pelaez Fernandez I, et al
    SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).
    Clin Transl Oncol. 2022 Mar 26. pii: 10.1007/s12094-022-02815.
    PubMed    
    Abstract available

  21. YU K, Du Z, Xuan H, Chen Q, et al
    Comprehensive analysis based in silico study of organophosphate flame retardants - environmental explanation of bladder cancer progression.
    Environ Toxicol Pharmacol. 2022;92:103851.
    PubMed    
    Abstract available

  22. TAGUCHI S, Watanabe M, Tambo M, Machida H, et al
    Proposal for a New Vesical Imaging-Reporting and Data System (VI-RADS)-Based Algorithm for the Management of Bladder Cancer: A Paradigm Shift From the Current Transurethral Resection of Bladder Tumor (TURBT)-Dependent Practice.
    Clin Genitourin Cancer. 2022 Mar 4. pii: S1558-7673(22)00047.
    PubMed    
    Abstract available

  23. FREITAS NR, Vieira PM, Cordeiro A, Tinoco C, et al
    Detection of bladder cancer with feature fusion, transfer learning and CapsNets.
    Artif Intell Med. 2022;126:102275.
    PubMed    
    Abstract available

  24. MALLY D, Pfister D, Heidenreich A, Albers P, et al
    [Does robotic radical cystectomy affect oncological outcomes in bladder cancer patients?]
    Aktuelle Urol. 2022;53:153-158.
    PubMed    
    Abstract available

  25. FAN W, Xiong Q, Ge Y, Liu T, et al
    Identifying the grade of bladder cancer cells using microfluidic chips based on impedance.
    Analyst. 2022 Mar 28. doi: 10.1039/d2an00026.
    PubMed    
    Abstract available

  26. ZHANG L, Shao G, Shao J, Zhao J, et al
    PRMT5-activated c-Myc promote bladder cancer proliferation and invasion through up-regulating NF-kappaB pathway.
    Tissue Cell. 2022;76:101788.
    PubMed    
    Abstract available

  27. DANCIK GM, Theodorescu D
    Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314.
    Eur Urol Focus. 2022 Mar 23. pii: S2405-4569(22)00067.
    PubMed    
    Abstract available

  28. BUAC NP, Khusid JA, Sturgis MR, Gupta M, et al
    Disparities in patient and system factors explain racial/ethnic disparities in delayed time to treatment in muscle invasive bladder cancer.
    Urol Oncol. 2022 Mar 23. pii: S1078-1439(22)00060.
    PubMed    
    Abstract available

  29. OKA T, Matsuzaki K, Izumi H, Nonomura D, et al
    Osteosarcoma of the bladder: a case report.
    J Med Case Rep. 2022;16:118.
    PubMed    
    Abstract available

  30. LI K, Yang X, Zhuang J, Cai L, et al
    External validation of Pentafecta in patients undergoing laparoscopic radical cystectomy: results from a high-volume center.
    BMC Urol. 2022;22:41.
    PubMed    
    Abstract available

  31. KAWAI T, Taguchi S, Nakagawa T, Kamei J, et al
    Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis.
    J Immunother Cancer. 2022;10.
    PubMed    
    Abstract available

  32. CHEN C, Shang A, Sun Z, Gao Y, et al
    Urinary Exosomal Long Noncoding RNA TERC as a Noninvasive Diagnostic and Prognostic Biomarker for Bladder Urothelial Carcinoma.
    J Immunol Res. 2022;2022:9038808.
    PubMed    
    Abstract available

  33. KADKHODA S, Ghafouri-Fard S
    Function of miRNA-145-5p in the pathogenesis of human disorders.
    Pathol Res Pract. 2022;231:153780.
    PubMed    
    Abstract available

  34. RIZZO A, Mollica V, Santoni M, Ricci AD, et al
    Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.
    Future Oncol. 2022;18:739-748.
    PubMed    
    Abstract available

  35. SAMADDAR S, Mazur J, Sargent J, Thompson DH, et al
    Immunostimulatory Response of RWFV Peptide-Targeted Lipid Nanoparticles on Bladder Tumor Associated Cells.
    ACS Appl Bio Mater. 2021;4:3178-3188.
    PubMed    
    Abstract available

  36. HENG HG, Ramos-Vara JA, Fulkerson CM, Fourez LM, et al
    Ultrasonographic detection of apex nodules in the urinary bladder of Scottish Terriers.
    Vet Radiol Ultrasound. 2022;63:234-239.
    PubMed    
    Abstract available

  37. LOUAR M, Morel-Journel N, Ruffion A, Carnicelli D, et al
    Female Sexual Function and Body Image After Urinary Diversion for Benign Conditions.
    J Sex Med. 2022;19:263-269.
    PubMed    
    Abstract available

  38. BROSE A, Krombach GA, Roller FC

    Rofo. 2022;194:205-207.
    PubMed    


  39. SASAKI Y, Takahashi M, Fukuta K, Shiozaki K, et al
    The patient-side surgeon plays a key role in facilitating robot-assisted intracorporeal ileal conduit urinary diversion in men.
    J Robot Surg. 2022;16:437-444.
    PubMed    
    Abstract available

  40. NIELENS N, Marot L, Baeck M
    Sporotrichoid distributed tuberculous panniculitis as a late complication of intravesical bacillus Calmette-Guerin (BCG) immunotherapy.
    Int J Infect Dis. 2022;117:247-250.
    PubMed    
    Abstract available

  41. DE BROT S, Lothion-Roy J, Grau-Roma L, White E, et al
    Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component.
    Vet Comp Oncol. 2022;20:38-49.
    PubMed    
    Abstract available

  42. VECCIA A, Carbonara U, Derweesh I, Mehrazin R, et al
    Single-stage Xi(R) robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes.
    Minerva Urol Nephrol. 2022;74:233-241.
    PubMed    
    Abstract available

  43. HIROTSU KE, Rana J, Wang JY, Raghavan SS, et al
    Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
    J Am Acad Dermatol. 2021;85:1610-1611.
    PubMed    


  44. DELL'OGLIO P, Mazzone E, Lambert E, Vollemaere J, et al
    The Effect of Surgical Experience on Perioperative and Oncological Outcomes After Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Evidence from a Referral Centre with Extensive Experience in Robotic Surgery.
    Eur Urol Focus. 2021;7:352-358.
    PubMed    
    Abstract available

  45. OURFALI S, Ohannessian R, Fassi-Fehri H, Pages A, et al
    Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guerin Connaught Strain for Bladder Cancer Patients.
    Eur Urol Focus. 2021;7:111-116.
    PubMed    
    Abstract available

  46. YANG J, Qi M, Fei X, Wang X, et al
    Hsa_circRNA_0088036 acts as a ceRNA to promote bladder cancer progression by sponging miR-140-3p.
    Cell Death Dis. 2022;13:322.
    PubMed    
    Abstract available

  47. STONE L
    Urinary VOCs as bladder cancer biomarkers.
    Nat Rev Urol. 2022 Apr 8. pii: 10.1038/s41585-022-00595.
    PubMed    


  48. SUN B, Bte Rahmat JN, Kim HJ, Mahendran R, et al
    Wirelessly Activated Nanotherapeutics for In Vivo Programmable Photodynamic-Chemotherapy of Orthotopic Bladder Cancer.
    Adv Sci (Weinh). 2022 Apr 7:e2200731. doi: 10.1002/advs.202200731.
    PubMed    
    Abstract available

  49. LAI LY, Tafuri SM, Ginier EC, Herrel LA, et al
    Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer.
    Cochrane Database Syst Rev. 2022;4:CD014887.
    PubMed    
    Abstract available

  50. ABEDI Z, MotieGhader H, Hosseini SS, Sheikh Beig Goharrizi MA, et al
    mRNA-miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis.
    Sci Rep. 2022;12:5885.
    PubMed    
    Abstract available

  51. MCLOUGHLIN LC, O'Halloran S, Tjong M, Ajib K, et al
    The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer.
    Urol Oncol. 2022 Apr 4. pii: S1078-1439(22)00072.
    PubMed    
    Abstract available

  52. XIONG Q, Feng D, Wang Z, Ying Y, et al
    Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer.
    Front Immunol. 2022;13:836939.
    PubMed    
    Abstract available

  53. MAEYAMA R, Ikeda M, Shimura S, Amano N, et al
    Patients with Non-Muscle Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guerin Intravesical Instillation Therapy.
    Chemotherapy. 2022 Apr 7. pii: 000524449. doi: 10.1159/000524449.
    PubMed    
    Abstract available

  54. YU J, Cai L, Chen C, Fu X, et al
    Cascade Path Augmentation Unet for Bladder Cancer Segmentation in MRI.
    Med Phys. 2022 Apr 7. doi: 10.1002/mp.15646.
    PubMed    
    Abstract available

  55. ABUHASANEIN S, Jahnson S, Aljabery F, Gardmark T, et al
    Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience.
    Scand J Urol. 2022 Apr 7:1-6. doi: 10.1080/21681805.2022.2058605.
    PubMed    
    Abstract available

  56. JIANG Y, Zhang Z, Wang X, Feng Z, et al
    A Novel Prognostic Factor TIPE2 in Bladder Cancer.
    Pathol Oncol Res. 2022;28:1610282.
    PubMed    
    Abstract available

  57. LI M, Che N, Jin Y, Li J, et al
    CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming.
    Onco Targets Ther. 2022;15:299-311.
    PubMed    
    Abstract available

  58. VAN DER HEIJDEN MS, Powles T, Petrylak D, de Wit R, et al
    Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.
    Nat Commun. 2022;13:1878.
    PubMed    
    Abstract available

  59. PATTENDEN T, Samaranayake D, Morton A, Thangasamy I, et al
    Bladder cancer in Aboriginal and Torres Strait Islander people living in Australia: a scoping review protocol.
    BMJ Open. 2022;12:e059144.
    PubMed    
    Abstract available

  60. ZEMLICKOVA B, Brisuda A
    Prognostic factors of early second transurethral resection of non-muscle invasive bladder cancer 10 years of experience of a referral center.
    Rozhl Chir. 2022;101:119-128.
    PubMed    
    Abstract available

  61. HORNAK J, Brisuda A, Babjuk M
    Management of BCG failure in non-muscle-invasive bladder cancer the present and the future.
    Rozhl Chir. 2022;101:108-113.
    PubMed    
    Abstract available

  62. GREER MD, Schaub SK, Bowen SR, Liao JJ, et al
    A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy.
    Adv Radiat Oncol. 2021;7:100858.
    PubMed    
    Abstract available

  63. YANG M, Wang B, Hou W, Yu H, et al
    Negative Effects of Stromal Neutrophils on T Cells Reduce Survival in Resectable Urothelial Carcinoma of the Bladder.
    Front Immunol. 2022;13:827457.
    PubMed    
    Abstract available

  64. XIA QD, Sun JX, Liu CQ, Xu JZ, et al
    Ferroptosis Patterns and Tumor Microenvironment Infiltration Characterization in Bladder Cancer.
    Front Cell Dev Biol. 2022;10:832892.
    PubMed    
    Abstract available

  65. LU D, Yang T, Tang N, Li C, et al
    A pH-Dependent rhodamine fluorophore with antiproliferative activity of bladder cancer in Vitro/Vivo and apoptosis mechanism.
    Eur J Med Chem. 2022;236:114293.
    PubMed    
    Abstract available

  66. ZABOR EC, Kaizer AM, Garrett-Mayer E, Hobbs BP, et al
    Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts.
    JCO Precis Oncol. 2022;6:e2100390.
    PubMed    
    Abstract available

  67. MONTEIRO CRA, Korkes F, Krutman-Zveibil D, Glina S, et al
    Fibroblast growth factor receptor 3 gene (FGFR3) mutations in high-grade muscle-invasive urothelial bladder cancer in a Brazilian population: evaluation and prevalence.
    Einstein (Sao Paulo). 2022;20:eAO6450.
    PubMed    
    Abstract available

  68. KE HL, Lee YC, Li WM, Wang CS, et al
    High Ubiquitin-Specific Protease 2a Expression Level Predicts Poor Prognosis in Upper Tract Urothelial Carcinoma.
    Appl Immunohistochem Mol Morphol. 2022;30:304-310.
    PubMed    
    Abstract available

  69. HAROLD JA, Casilla-Lennon M, Kenney PA, Ratner ES, et al
    Vesical clear cell adenocarcinoma of Mullerian origin treated conservatively with partial cystectomy.
    BMJ Case Rep. 2022;15.
    PubMed    
    Abstract available

  70. PIAO XM, Kim YU, Byun YJ, Zheng CM, et al
    Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy.
    Urol Oncol. 2022 Apr 2. pii: S1078-1439(21)00557.
    PubMed    
    Abstract available

  71. YAMASAKI M, Taoka R, Katakura K, Matsunaga T, et al
    The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma.
    BMC Urol. 2022;22:51.
    PubMed    
    Abstract available

  72. LIU L, Qiu M, Tan G, Liang Z, et al
    Correction to: miR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3.
    J Transl Med. 2022;20:153.
    PubMed    


  73. ADNAN S, Abu Bakar M, Khalil MAI, Fiaz S, et al
    Outcomes of Uretero-ileal Anastomosis in Bladder Cancer Cystectomies: Bricker vs. Wallace 1.
    Cureus. 2022;14:e22782.
    PubMed    
    Abstract available

  74. ZRAIK I, Krege S
    [Follow-up in superficial and metastatic bladder cancer].
    Urologe A. 2022 Apr 5. pii: 10.1007/s00120-022-01813.
    PubMed    
    Abstract available

  75. GURAL Z, Yucel S, Oskeroglu S, Agaoglu F, et al
    Urachal adenocarcinoma: A case report and review of the literature.
    J Cancer Res Ther. 2022;18:291-293.
    PubMed    
    Abstract available

  76. LI K, Wang F, Wang J, Fan C, et al
    Marital status independently predicts survival of patients with upper urinary tract urothelial carcinoma: A population-based study.
    J Cancer Res Ther. 2021;17:1709-1717.
    PubMed    
    Abstract available

  77. ELSHETRY ASF, El-Fawakry RM, Hamed EM, Metwally MI, et al
    Diagnostic accuracy and discriminative power of biparametric versus multiparametric MRI in predicting muscle-invasive bladder cancer.
    Eur J Radiol. 2022;151:110282.
    PubMed    
    Abstract available

  78. TAOKA R, Matsuoka Y, Yamasaki M, Kani N, et al
    Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2022 Apr 2:102838.
    PubMed    
    Abstract available

  79. THEODORESCU D, Li Z, Li X
    Sex differences in bladder cancer: emerging data and call to action.
    Nat Rev Urol. 2022 Apr 4. pii: 10.1038/s41585-022-00591.
    PubMed    


  80. ALHALABI O, Chen J, Zhang Y, Lu Y, et al
    MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
    Nat Commun. 2022;13:1797.
    PubMed    
    Abstract available

  81. TABER A, Christensen E, Lamy P, Nordentoft I, et al
    Author Correction: Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.
    Nat Commun. 2022;13:1916.
    PubMed    


  82. TALWAR HS, Kumar S, Mittal A, Narain TA, et al
    Incidental encounter of intraperitoneal tuberculosis during renal surgeries: A surgeon's dilemma.
    Indian J Tuberc. 2022;69:246-249.
    PubMed    
    Abstract available

  83. FAVORITO LA
    Upper tract urothelial carcinoma and bladder cancer in review in this number of International Brazilian Journal of Urology.
    Int Braz J Urol. 2022;48:386-388.
    PubMed    


  84. LI Z, Wang S, Chen Y, Huang Y, et al
    5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer.
    Dis Markers. 2022;2022:3117359.
    PubMed    
    Abstract available

  85. SHAO C, Sun A, Xue H, Di X, et al
    Three-Dimensional Ultrasound Images in the Assessment of Bladder Tumor Health Monitoring under Deep Learning Algorithms.
    Comput Math Methods Med. 2022;2022:9170274.
    PubMed    
    Abstract available

  86. YANG X, Lv H, Jiang W, Zhang J, et al
    Clinical Value Analysis of Xiaozheng Decoction Combined with Bladder Perfusion for Postoperative Treatment of Bladder Cancer and Its Effect on Serum miR-143 and miR-92a.
    J Healthc Eng. 2022;2022:8177674.
    PubMed    
    Abstract available

  87. CUI Y, Sun Z, Liu X, Zhang X, et al
    CT-based radiomics for the preoperative prediction of the muscle-invasive status of bladder cancer and comparison to radiologists' assessment.
    Clin Radiol. 2022 Mar 30. pii: S0009-9260(22)00130.
    PubMed    
    Abstract available

  88. YANISHI M, Kinoshita H
    Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury.
    BMC Nephrol. 2022;23:125.
    PubMed    
    Abstract available

  89. TAUBER R, von Amsberg G, De Santis M
    [Update on systemic treatment of urothelial cancer: therapy in transition].
    Aktuelle Urol. 2022;53:167-179.
    PubMed    
    Abstract available



  90. Aktuelle Urol. 2022;53:119-121.
    PubMed    




  91. Aktuelle Urol. 2022;53:116.
    PubMed    




  92. Aktuelle Urol. 2022;53:114-116.
    PubMed    




  93. Aktuelle Urol. 2022;53:112-114.
    PubMed    




  94. Aktuelle Urol. 2022;53:110-112.
    PubMed    


  95. NIEGISCH G

    Aktuelle Urol. 2022;53:135-136.
    PubMed    


  96. ZHAO C, Xiong K, Ji Z, Liu F, et al
    The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis.
    Oxid Med Cell Longev. 2022;2022:8297011.
    PubMed    
    Abstract available

  97. HURST CD, Cheng G, Platt FM, Alder O, et al
    Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling.
    J Pathol Clin Res. 2022;8:279-293.
    PubMed    
    Abstract available

  98. CASARIN M, Fortunato TM, Imran S, Todesco M, et al
    Porcine Small Intestinal Submucosa (SIS) as a Suitable Scaffold for the Creation of a Tissue-Engineered Urinary Conduit: Decellularization, Biomechanical and Biocompatibility Characterization Using New Approaches.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  99. CINQUE A, Capasso A, Vago R, Floris M, et al
    MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  100. LIU E, Guan X, Wei R, Jiang Z, et al
    Association Between Radiotherapy and Death From Cardiovascular Disease Among Patients With Cancer: A Large Population-Based Cohort Study.
    J Am Heart Assoc. 2022;11:e023802.
    PubMed    
    Abstract available

  101. CHAN TC, Hsing CH, Shiue YL, Huang SK, et al
    Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression.
    Cells. 2022;11.
    PubMed    
    Abstract available

  102. DENG M, Wang N, Li Z, Chen R, et al
    FXR1 can bind with the CFIm25/CFIm68 complex and promote the progression of urothelial carcinoma of the bladder by stabilizing TRAF1 mRNA.
    Cell Death Dis. 2022;13:170.
    PubMed    
    Abstract available

  103. BOLENZ C, Ohlmann CH, Gschwend J
    [Do's and Dont's for radical cystectomy and urinary diversion - how to minimise postoperative complications].
    Aktuelle Urol. 2022;53:159-166.
    PubMed    
    Abstract available

  104. YIN Y, Song L, Shi D, Liu B, et al
    Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non-Small-Cell Lung Cancer and Other Cancer Types.
    JCO Precis Oncol. 2022;6:e2100325.
    PubMed    
    Abstract available

  105. BOULEFTOUR W, Guillot A, Magne N
    The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review.
    Mol Cancer Ther. 2022;21:493-501.
    PubMed    
    Abstract available

  106. BERNARDO C, Eriksson P, Marzouka NA, Liedberg F, et al
    Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours: An integrated immunohistochemical analysis.
    Hum Pathol. 2022;122:11-24.
    PubMed    
    Abstract available

  107. WOJCIK EM, Kurtycz DFI, Rosenthal DL
    We'll always have Paris The Paris System for Reporting Urinary Cytology 2022.
    J Am Soc Cytopathol. 2022;11:62-66.
    PubMed    
    Abstract available

  108. XIAO JF, Kua LF, Ding LW, Sun QY, et al
    KDM6A Depletion in Breast Epithelial Cells Leads to Reduced Sensitivity to Anticancer Agents and Increased TGFbeta Activity.
    Mol Cancer Res. 2022;20:637-649.
    PubMed    
    Abstract available

  109. GAO X, Lin B, Lin Q, Ye T, et al
    A HALP score-based prediction model for survival of patients with the upper tract urothelial carcinoma undergoing radical nephroureterectomy.
    Bosn J Basic Med Sci. 2022;22:280-290.
    PubMed    
    Abstract available

  110. ZHANG H, Lu X, Huang G, Hua M, et al
    A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
    BMC Med Genomics. 2022;15:1.
    PubMed    
    Abstract available

  111. KOBAYASHI G, Uraoka N, Sentani K, Shibata J, et al
    Cytological and histological findings of upper tract mucinous urothelial carcinoma with clear cell component: A case report and review of literature.
    Diagn Cytopathol. 2022;50:E129-E135.
    PubMed    
    Abstract available

  112. ALGER J, Mallahan C, Deng T, Marshall J, et al
    Neuroendocrine tumor causing ureteral obstruction in a patient with prior ileal conduit.
    Can J Urol. 2021;28:10953-10955.
    PubMed    
    Abstract available

  113. O'CONNOR A, Sabri S, Muhammad K
    The use of methylene blue to aid identification of ileal conduit anatomy during subsequent surgery.
    Ann R Coll Surg Engl. 2022;104:1.
    PubMed    


  114. SHANG D, Li G, Zhang C, Liu Y, et al
    Synergistic inhibitory effects of 5-aza-2'-deoxycytidine and cisplatin on urothelial carcinoma growth via suppression of TGFBI-MAPK signaling pathways.
    Biochem Cell Biol. 2022;100:115-124.
    PubMed    
    Abstract available

  115. ALLISON DB, Kates M, VandenBussche CJ
    Indeterminate atypia in urinary tract cytology: Does it really matter?
    Diagn Cytopathol. 2022;50:176-183.
    PubMed    
    Abstract available

  116. LOGHIN A, Nechifor-Boila A, Borda A, Nechifor-Boila IA, et al
    Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
    Virchows Arch. 2022;480:303-313.
    PubMed    
    Abstract available


  117. Bicyclic Peptide Makes Targeting EphA2 Possible.
    Cancer Discov. 2021;11:2951-2952.
    PubMed    
    Abstract available

  118. KAMEI J, Fujisaki A, Saito K, Sugihara T, et al
    Less invasive and equivalent short-term outcomes with simultaneous en bloc robot-assisted radical cystectomy and laparoscopic nephroureterectomy: Comparison with conventional open radical cystectomy and nephroureterectomy.
    Asian J Endosc Surg. 2022;15:255-260.
    PubMed    
    Abstract available

  119. VOLKEL C, De Wispelaere N, Weidemann S, Gorbokon N, et al
    Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.
    Virchows Arch. 2022;480:433-447.
    PubMed    
    Abstract available

  120. MURAKAMI K, Kamat AM, Dai Y, Pagano I, et al
    Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study.
    Cancer Biomark. 2022;33:151-157.
    PubMed    
    Abstract available

  121. PATEL SH
    Clinician's commentary: Atypia in urinary tract cytology specimens.
    Diagn Cytopathol. 2022;50:184-185.
    PubMed    
    Abstract available

  122. TATJANA A, Tjota MY, O'Donnell PH, Eggener SE, et al
    EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.
    Virchows Arch. 2022;480:487-492.
    PubMed    
    Abstract available

  123. SHARMA G, Yadav AK, Pareek T, Kaundal P, et al
    Impact of pathological factors on survival in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis.
    Int Braz J Urol. 2022;48:406-455.
    PubMed    
    Abstract available

  124. LUNA-VELEZ MV, Dijkstra JJ, Heuschkel MA, Smit FP, et al
    Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder.
    Mol Oncol. 2021;15:1882-1900.
    PubMed    
    Abstract available

  125. HUSSAIN SA, Lester JF, Jackson R, Gornall M, et al
    Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
    Lancet Oncol. 2022 Apr 11. pii: S1470-2045(22)00158.
    PubMed    
    Abstract available

  126. LI X, Zhou L, Lu T, Zhang L, et al
    Constructing an immune- and ferroptosis-related lncRNA signature to predict the immune landscape of human bladder cancer.
    J Clin Lab Anal. 2022 Apr 14:e24389. doi: 10.1002/jcla.24389.
    PubMed    
    Abstract available

  127. MAO C, Gao Y, Wan M, Xu N, et al
    Identification of glycolysis-associated long non-coding RNA regulatory subtypes and construction of prognostic signatures by transcriptomics for bladder cancer.
    Funct Integr Genomics. 2022 Apr 14. pii: 10.1007/s10142-022-00845.
    PubMed    
    Abstract available

  128. WANG F, Dong X, Yang F, Xing N, et al
    Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
    Front Genet. 2022;13:831146.
    PubMed    
    Abstract available

  129. XIA QD, Sun JX, Xun Y, Xiao J, et al
    SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer.
    Front Immunol. 2022;13:864156.
    PubMed    
    Abstract available

  130. SUN J, Ma X, Ying Y, Wang W, et al
    SMAD3 and FTO are involved in miR-5581-3p-mediated inhibition of cell migration and proliferation in bladder cancer.
    Cell Death Discov. 2022;8:199.
    PubMed    
    Abstract available

  131. OU L, Wei Z, Xu J, Li W, et al
    FAM107A as a Tumor Suppressor in Bladder Cancer Inhibits Cell Proliferation, Migration, and Invasion.
    Ann Clin Lab Sci. 2022;52:260-268.
    PubMed    
    Abstract available

  132. SHARMA G, Sharma A, Krishna M, Ahluwalia P, et al
    Diagnostic performance of minichromosome maintenance 5 (MCM5) in bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2022 Apr 9. pii: S1078-1439(22)00075.
    PubMed    
    Abstract available

  133. YAMAMOTO A, Kawashima A, Uemura T, Yamamichi G, et al
    Biological distinction between grades 2 and 3 with respect to intravesical recurrence in T1 high-grade bladder tumors: a retrospective study.
    BMC Urol. 2022;22:59.
    PubMed    
    Abstract available

  134. ABUHASANEIN S, Hansen C, Vojinovic D, Jahnson S, et al
    Computed tomography urography with corticomedullary phase can exclude urinary bladder cancer with high accuracy.
    BMC Urol. 2022;22:60.
    PubMed    
    Abstract available

  135. AL-ZALABANI AH, Wesselius A, Yi-Wen Yu E, van den Brandt P, et al
    Tea consumption and risk of bladder cancer in the Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study: Pooled analysis of 12 international cohort studies.
    Clin Nutr. 2022;41:1122-1130.
    PubMed    
    Abstract available

  136. DING K, Wang L, Zhu J, He D, et al
    Photo-Enhanced Chemotherapy Performance in Bladder Cancer Treatment via Albumin Coated AIE Aggregates.
    ACS Nano. 2022 Apr 12. doi: 10.1021/acsnano.1c10770.
    PubMed    
    Abstract available

  137. LI G, Wang Y, Guo XB, Zhao B, et al
    CDC42 Regulates Cell Proliferation and Apoptosis in Bladder Cancer via the IQGAP3-Mediated Ras/ERK Pathway.
    Biochem Genet. 2022 Apr 12. pii: 10.1007/s10528-022-10223.
    PubMed    
    Abstract available

  138. ABDULLAH O, Parashar D, Mustafa IJ, Young AM, et al
    Venous Thromboembolism Rate in Patients With Bladder Cancer According to the Type of Treatment: A Systematic Review.
    Cureus. 2022;14:e22945.
    PubMed    
    Abstract available

  139. LIN MH, Islam A, Liu YH, Weng CW, et al
    Antibiotic heliomycin and its water-soluble 4-aminomethylated derivative provoke cell death in T24 bladder cancer cells by targeting sirtuin 1 (SIRT1).
    Am J Cancer Res. 2022;12:1042-1055.
    PubMed    
    Abstract available

  140. QIAN H, Wang Y, Ma Z, Qian L, et al
    Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy.
    Int J Nanomedicine. 2022;17:1635-1646.
    PubMed    
    Abstract available

  141. WARD DG, Baxter L, Ott S, Gordon NS, et al
    Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.
    Eur Urol Oncol. 2022 Apr 8. pii: S2588-9311(22)00036.
    PubMed    
    Abstract available

  142. HOLM JS, Funt SA, Borch A, Munk KK, et al
    Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
    Nat Commun. 2022;13:1935.
    PubMed    
    Abstract available

  143. XU L, Su B, Mo L, Zhao C, et al
    Norcantharidin Induces Immunogenic Cell Death of Bladder Cancer Cells through Promoting Autophagy in Acidic Culture.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  144. THOMAS J, Sonpavde G
    Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  145. LU YT, Xu T, Iqbal M, Hsieh TC, et al
    FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  146. SJODAHL G, Abrahamsson J, Bernardo C, Eriksson P, et al
    Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer-A Narrative Review.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  147. WEIDLE UH, Birzele F
    Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.
    Cancer Diagn Progn. 2021;1:245-263.
    PubMed    
    Abstract available

  148. LI X, Liu H, Lv C, Du J, et al
    Gypenoside-Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer.
    Biomed Res Int. 2022;2022:9304552.
    PubMed    
    Abstract available

  149. MA Q, Xu C, Han X, Wang X, et al
    The effects of modified RNA-binding proteins HuR on the biological behavior of the bladder cancer T24 cell line.
    Transl Androl Urol. 2022;11:348-357.
    PubMed    
    Abstract available

  150. LIU F, Liu X, Deng W, Yang X, et al
    Overexpression of F-box and WD repeat domain containing 7 prevents tumor growth of bladder cancer cells through regulating SREBP1a.
    Transl Androl Urol. 2022;11:367-376.
    PubMed    
    Abstract available

  151. LI YD, Gao L, Gou YQ, Tan W, et al
    Age of menarche and primary bladder cancer risk: A meta-analysis and systematic review.
    Urol Oncol. 2022 Apr 7. pii: S1078-1439(22)00074.
    PubMed    
    Abstract available

  152. WATANABE K, Tamura K, Matsushita Y, Watanabe H, et al
    Significance of 5-Aminolevulinic Acid-mediated Photodynamic Diagnosis Following Standard Transurethral Resection in Non-muscle Invasive Bladder Cancer.
    Cancer Diagn Progn. 2021;1:201-205.
    PubMed    
    Abstract available

  153. LIN N, Chen L, Zhang Y, Yang Y, et al
    KIF4A promotes tumor progression of bladder cancer via CXCL5 dependent myeloid-derived suppressor cells recruitment.
    Sci Rep. 2022;12:6015.
    PubMed    
    Abstract available

  154. SHINWARI K, Chen Z, Liu G, Chen L, et al
    Identification of The Immune Subtype Among Muscle-invasive Bladder Cancer Patients by Multiple Datasets.
    Acta Med Indones. 2022;54:62-71.
    PubMed    
    Abstract available

  155. REESINK DJ, van de Garde EMW, van der Nat P, Somford DM, et al
    Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.
    World J Urol. 2022 Apr 10. pii: 10.1007/s00345-022-03987.
    PubMed    
    Abstract available

  156. YE JB, Chen Q, Zeng K, Li XB, et al
    Eosinophilic cystitis complicated with cystitis glandularis: a case report.
    BMC Urol. 2022;22:55.
    PubMed    
    Abstract available

  157. YILDIRIM S, Ozkan EI, Sadioglu A, Gonul II, et al
    Bone in bladder.
    J Nephrol. 2022;35:1043-1044.
    PubMed    


  158. NIKOLOS F, Hayashi K, Hoi XP, Alonzo ME, et al
    Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors.
    Nat Commun. 2022;13:1487.
    PubMed    
    Abstract available

  159. RUSSELL BM, Boussi L, Bellmunt J
    Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?
    Drugs Aging. 2022;39:271-284.
    PubMed    
    Abstract available

  160. VOUTSADAKIS IA
    Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
    Curr Oncol. 2022;29:1390-1407.
    PubMed    
    Abstract available

  161. HASHIMOTO H, Tanaka Y, Murata M, Ito T, et al
    Nectin-4: a Novel Therapeutic Target for Skin Cancers.
    Curr Treat Options Oncol. 2022;23:578-593.
    PubMed    
    Abstract available

  162. DAUBISSE-MARLIAC L, Grosclaude P, Carulla M, Parada D, et al
    Registration of Urothelial Tumours in Cancer Registries: How to Improve and Make It More Useful?
    Int J Environ Res Public Health. 2022;19.
    PubMed    
    Abstract available

  163. UNGARO A, Tucci M, Audisio A, Di Prima L, et al
    Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
    Cells. 2022;11.
    PubMed    
    Abstract available

  164. MATHEW THOMAS V, Tripathi N, Agarwal N, Swami U, et al
    Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
    Expert Rev Anticancer Ther. 2022;22:335-341.
    PubMed    
    Abstract available

  165. DIAMANTOPOULOS LN, Korentzelos D, Alevizakos M, Wright JL, et al
    Sarcomatoid Urothelial Carcinoma: A Population-Based Study of Clinicopathologic Characteristics and Survival Outcomes.
    Clin Genitourin Cancer. 2022;20:139-147.
    PubMed    
    Abstract available

  166. TALUKDER R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, et al
    Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
    Clin Genitourin Cancer. 2022;20:165-175.
    PubMed    
    Abstract available

  167. WILSON J, Drach D, Zanghi J, Siegert J, et al
    Improving practice patterns in patients with newly diagnosed bladder masses treated with transurethral resection.
    J Osteopath Med. 2022;122:169-173.
    PubMed    
    Abstract available

  168. LIN TW, Lee HY, Yang SF, Li CC, et al
    ASO Visual Abstract: Perineural Invasion is a Powerful Prognostic Factor for Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.
    Ann Surg Oncol. 2022;29:3320-3321.
    PubMed    


  169. ADIBI M, McCormick B, Economides MP, Petros F, et al
    Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:176-182.
    PubMed    
    Abstract available

  170. SPARWASSER P, Epple S, Thomas A, Dotzauer R, et al
    First completely robot-assisted retroperitoneal nephroureterectomy with bladder cuff: a step-by-step technique.
    World J Urol. 2022;40:1019-1026.
    PubMed    
    Abstract available

  171. FERRO M, Chiujdea S, Musi G, Lucarelli G, et al
    Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis.
    Clin Genitourin Cancer. 2022;20:e166-e172.
    PubMed    
    Abstract available

  172. DEL GIUDICE F, van Uem S, Li S, Vilson FL, et al
    Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and
    Clin Genitourin Cancer. 2022;20:198.
    PubMed    
    Abstract available

  173. RAGGI D, Giannatempo P, Marandino L, Pierantoni F, et al
    Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
    Clin Genitourin Cancer. 2022;20:155-164.
    PubMed    
    Abstract available

  174. JINDAL T, Chou J, Friedlander T, Barata PC, et al
    Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.
    Clin Genitourin Cancer. 2022;20:189-194.
    PubMed    
    Abstract available

  175. LAYMON M, Mosbah A, Hashem A, Mahmoud O, et al
    Oncologic Outcomes of Squamous Cell Carcinoma Versus Urothelial Carcinoma With Squamous Differentiation After Radical Cystectomy for Bladder Carcinoma.
    Clin Genitourin Cancer. 2022;20:148-154.
    PubMed    
    Abstract available

  176. KARAM A, Mjaess G, Albisinni S, El Daccache Y, et al
    Uncovering the role of urinary microbiota in urological tumors: a systematic review of literature.
    World J Urol. 2022;40:951-964.
    PubMed    
    Abstract available

  177. LIN TW, Lee HY, Yang SF, Li CC, et al
    Perineural Invasion is a Powerful Prognostic Factor for Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy.
    Ann Surg Oncol. 2022;29:3306-3317.
    PubMed    
    Abstract available

  178. LIN TW, Yeh HC
    ASO Author Reflections: Prognostic Significance of Perineural Invasion in Upper Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2022;29:3318-3319.
    PubMed    


  179. TANG CH, Chen YC, Hsieh WT, Sue YM, et al
    Gender and Age Differences of Genitourinary Cancers Among Chronic Dialysis Patients in Taiwan.
    Clin Genitourin Cancer. 2022;20:e126-e134.
    PubMed    
    Abstract available

  180. ABUHELWA AY, Bellmunt J, Kichenadasse G, McKinnon RA, et al
    Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy.
    Clin Genitourin Cancer. 2022;20:132-138.
    PubMed    
    Abstract available

  181. MIYAKE M, Shimizu T, Nishimura N, Kiba K, et al
    Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:196.
    PubMed    
    Abstract available

  182. KOSIBA M, Stolzenbach LF, Colla Ruvolo C, Nocera L, et al
    Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder.
    Clin Genitourin Cancer. 2022;20:195.
    PubMed    
    Abstract available

  183. GRIVAS P, Huber C, Pawar V, Roach M, et al
    Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies.
    Clin Genitourin Cancer. 2022;20:114-122.
    PubMed    
    Abstract available

  184. KOBAYASHI G, Hayashi T, Sentani K, Babasaki T, et al
    Clinicopathological significance of claspin overexpression and its efficacy as a novel biomarker for the diagnosis of urothelial carcinoma.
    Virchows Arch. 2022;480:621-633.
    PubMed    
    Abstract available

  185. MONTOYA-CERRILLO D, Briski LM, Jorda M, Kryvenko ON, et al
    Utility of GATA-3 and Cytokeratin 5/6 Immunostains in Separating Condyloma Acuminatum Arising in the Urinary Tract From Non-Invasive Papillary Urothelial Carcinoma.
    Int J Surg Pathol. 2022;30:260-264.
    PubMed    
    Abstract available

  186. MALDE S, Grover S, Raj S, Yuan C, et al
    A Systematic Review of the Efficacy and Safety of Outpatient Bladder Tumour Ablation.
    Eur Urol Focus. 2022;8:141-151.
    PubMed    
    Abstract available

  187. SEISEN T, Mari A, Campi R, Peyronnet B, et al
    Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review.
    Eur Urol Focus. 2021;7:1075-1083.
    PubMed    
    Abstract available

  188. DELL'OGLIO P, Turri F, Larcher A, D'Hondt F, et al
    Definition of a Structured Training Curriculum for Robot-assisted Radical Cystectomy with Intracorporeal Ileal Conduit in Male Patients: A Delphi Consensus Study Led by the ERUS Educational Board.
    Eur Urol Focus. 2022;8:160-164.
    PubMed    
    Abstract available

  189. TURAL D, Olmez OF, Sumbul AT, Artac M, et al
    Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
    Eur Urol Focus. 2021;7:1061-1066.
    PubMed    
    Abstract available

  190. DEUKER M, Stolzenbach LF, Colla Ruvolo C, Nocera L, et al
    Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study.
    Eur Urol Focus. 2021;7:1332-1338.
    PubMed    
    Abstract available

  191. MASTROIANNI R, Brassetti A, Krajewski W, Zdrojowy R, et al
    Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival.
    Eur Urol Focus. 2021;7:1324-1331.
    PubMed    
    Abstract available

  192. NECCHI A, Madison R, Pal SK, Ross JS, et al
    Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Eur Urol Focus. 2021;7:1339-1346.
    PubMed    
    Abstract available

  193. FURRER MA, Kiss B, Wuthrich PY, Thomas BC, et al
    Long-term Outcomes of Cystectomy and Crossfolded Ileal Reservoir Combined with an Afferent Tubular Segment for Heterotopic Continent Urinary Diversion: A Longitudinal Single-centre Study.
    Eur Urol Focus. 2021;7:629-637.
    PubMed    
    Abstract available

  194. PANG KH, Thomas F, Novara G, Din OS, et al
    The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre.
    Eur Urol Focus. 2021;7:554-565.
    PubMed    
    Abstract available

  195. CONG Z, Tang S, Xie L, Yang M, et al
    Magnetic-Powered Janus Cell Robots Loaded with Oncolytic Adenovirus for Active and Targeted Virotherapy of Bladder Cancer.
    Adv Mater. 2022 Apr 22:e2201042. doi: 10.1002/adma.202201042.
    PubMed    
    Abstract available

  196. GRUNEWALD CM, Niegisch G, Albers P
    Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011.
    Eur Urol Focus. 2022 Apr 18. pii: S2405-4569(22)00078.
    PubMed    
    Abstract available

  197. ZHAO H, Chen Z, Fang Y, Su M, et al
    Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
    J Immunol Res. 2022;2022:1793005.
    PubMed    
    Abstract available

  198. D'ELIA C, Trenti E, Krause P, Pycha A, et al
    Xpert(R) bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: preliminary results.
    Ther Adv Urol. 2022;14:17562872221090320.
    PubMed    
    Abstract available

  199. HWANG TI, Chen PC, Tsai TF, Lin JF, et al
    Hsa-miR-30a-3p overcomes the acquired protective autophagy of bladder cancer in chemotherapy and suppresses tumor growth and muscle invasion.
    Cell Death Dis. 2022;13:390.
    PubMed    
    Abstract available

  200. XU H, Shi HL, Hao JW, Shu KP, et al
    [Casticin inhibits the proliferation, migration and invasion of bladder cancer cells by inhibition of TM7SF4 expression].
    Zhonghua Zhong Liu Za Zhi. 2022;44:334-340.
    PubMed    
    Abstract available

  201. SU Z, Monshaugen I, Wilson B, Wang F, et al
    TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer.
    Nat Commun. 2022;13:2165.
    PubMed    
    Abstract available

  202. UEMURA T, Ishibashi T, Pae S, Shirakawa N, et al
    [CLINICAL STUDY OF OPEN RADICAL CYSTECTOMY AND ILEAL CONDUIT CONSTRUCTION FOR BLADDER CANCER: RESULTS OF 15-YEAR SINGLE CENTER EXPERIENCE].
    Nihon Hinyokika Gakkai Zasshi. 2021;112:89-95.
    PubMed    
    Abstract available

  203. MATSUMURA S, Yoshida T, Imanaka T, Yamanaka K, et al
    [OUTCOMES OF BLADDER CANCER IN NONAGENARIANS].
    Nihon Hinyokika Gakkai Zasshi. 2021;112:58-64.
    PubMed    
    Abstract available

  204. MAEDA K, Mori Y, Nakamura M, Harada Y, et al
    [SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION AS A SIDE EFFECT OF CHEMOTHERAPY FOR URACHAL CARCINOMA: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2021;112:100-104.
    PubMed    
    Abstract available

  205. XIA Y, Ge M, Xia L, Shan G, et al
    CTSV (cathepsin V) promotes bladder cancer progression by increasing NF-kappaB activity.
    Bioengineered. 2022;13:10180-10190.
    PubMed    
    Abstract available

  206. LIU T, Li T, Zheng Y, Xu X, et al
    Evaluating adipose-derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancer.
    Cancer Med. 2022 Apr 20. doi: 10.1002/cam4.4745.
    PubMed    
    Abstract available

  207. TAE BS, Oh JJ, Jeong BC, Ku JH, et al
    Catheter-associated urinary tract infections in patients who have undergone radical cystectomy for bladder cancer: A prospective randomized clinical study of two silicone catheters (clinical benefit of antibiotic silicone material).
    Investig Clin Urol. 2022 Mar 28. pii: 63.e32. doi: 10.4111/icu.20210436.
    PubMed    
    Abstract available

  208. JUNG A, Crandell JL, Nielsen ME, Smith SK, et al
    Relationships among uncertainty, post-traumatic stress disorder symptoms, and quality of life in non-muscle-invasive bladder cancer survivors.
    Support Care Cancer. 2022 Apr 18. pii: 10.1007/s00520-022-07034.
    PubMed    
    Abstract available

  209. BIERI U, Scharl M, Sigg S, Szczerba BM, et al
    Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol.
    BMJ Open. 2022;12:e061421.
    PubMed    
    Abstract available

  210. HARDY CSC, Ghaedi H, Slotman A, Sjodahl G, et al
    Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers.
    J Histochem Cytochem. 2022 Apr 19:221554221095530.
    PubMed    
    Abstract available

  211. YAMUC E, Barisik NO, Sensu S, Tarhan F, et al
    Correlation of REG1A, Claudin 7 and Ki67 expressions with tumor recurrence and prognostic factors in superficial urothelial urinary bladder carcinomas.
    Indian J Pathol Microbiol. 2022;65:355-361.
    PubMed    
    Abstract available

  212. ELIZALDE BENITO FX, Sieso Gracia MR, Dolezal P, Martin Anoro LF, et al
    Abdominal mass as the first manifestation of bladder tumor.
    Arch Esp Urol. 2022;75:306-307.
    PubMed    


  213. RUIBAL GAGO L
    [Altered urinary pH as an aetiology of granulomas in urostomised patients.]
    Arch Esp Urol. 2022;75:296-299.
    PubMed    
    Abstract available

  214. SALAS E, Enguita L, Espilez R, Santander C, et al
    [Lymphoepithelioma-like bladder tumor. A rare variant.]
    Arch Esp Urol. 2022;75:300-305.
    PubMed    
    Abstract available

  215. LEI Y, Jiao D, Yao Z, Wang L, et al
    Prognostic values of preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and lymphocyte- to-monocyte ratio for patients with muscle- invasive bladder cancer undergoing radical cystectomy.
    Arch Esp Urol. 2022;75:287-294.
    PubMed    
    Abstract available

  216. WANG F, Yang J
    Correlations between forkhead box D1 expression and clinicopathological characteristics of patients with bladder cancer and influence on biological behaviors of bladder cancer cells.
    Arch Esp Urol. 2022;75:274-281.
    PubMed    
    Abstract available

  217. CHENG J, Yang Q, Han X, Wang H, et al
    Yin Yang 1-stimulated long noncoding RNA bladder cancer-associated transcript 1 upregulation facilitates esophageal carcinoma progression via the microRNA-5590-3p/programmed cell death-ligand 1 pathway.
    Bioengineered. 2022;13:10244-10257.
    PubMed    
    Abstract available

  218. HUANG M, Dong W, Xie R, Wu J, et al
    HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program.
    Cancer Commun (Lond). 2022 Apr 18. doi: 10.1002/cac2.12284.
    PubMed    
    Abstract available

  219. GU H, Liang C
    Construction and Validation of a 15-Top-prognostic-gene-based Signature to Indicate the Dichotomized Clinical Outcome and Response to Targeted Therapy for Bladder Cancer Patients.
    Front Cell Dev Biol. 2022;10:725024.
    PubMed    
    Abstract available

  220. HUANG Z, Gao H, Qing L, Wang B, et al
    A long noncoding RNA GTF2IRD2P1 suppresses cell proliferation in bladder cancer by inhibiting the Wnt/betacatenin signaling pathway.
    PeerJ. 2022;10:e13220.
    PubMed    
    Abstract available

  221. RAZZAGHDOUST A, Muhammadnejad S, Parvin M, Mofid B, et al
    Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer.
    Iran J Basic Med Sci. 2021;24:1650-1655.
    PubMed    
    Abstract available

  222. SORCE G, Chierigo F, Flammia RS, Hoeh B, et al
    Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity.
    Urol Oncol. 2022 Apr 14. pii: S1078-1439(22)00105.
    PubMed    
    Abstract available

  223. DANESHMAND S, Brummelhuis ISG, Pohar KS, Steinberg GD, et al
    The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
    Urol Oncol. 2022 Apr 14. pii: S1078-1439(22)00059.
    PubMed    
    Abstract available

  224. WANG SS, Zhai GQ, Chen G, Huang ZG, et al
    Decreased expression of transcription factor Homeobox A11 and its potential target genes in bladder cancer.
    Pathol Res Pract. 2022;233:153847.
    PubMed    
    Abstract available

  225. MUZAAIL HH, El-Assmy A, Harraz AM, Awadalla A, et al
    Prediction of recurrence of non-muscle invasive bladder cancer: The role of androgen receptor and miRNA-2909.
    Urol Oncol. 2022 Apr 13. pii: S1078-1439(22)00078.
    PubMed    
    Abstract available

  226. GONZALEZ-PADILLA DA, Subiela JD, Gonzalez-Diaz A, Hernandez-Arroyo M, et al
    Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center.
    Urol Oncol. 2022 Apr 14. pii: S1078-1439(22)00067.
    PubMed    
    Abstract available

  227. TEPLITSKY SL, Hensley PJ, Bettis A, James A, et al
    Operative duration and short term morbidity and mortality following radical cystectomy with urinary diversion.
    Can J Urol. 2022;29:11087-11094.
    PubMed    
    Abstract available

  228. DIETRICH F, Cappellari AR, Filippi-Chiela EC, de Paula PB, et al
    High P2X6 receptor expression in human bladder cancer predicts good survival prognosis.
    Mol Cell Biochem. 2022 Apr 16. pii: 10.1007/s11010-022-04425.
    PubMed    
    Abstract available

  229. AL-ZUBAIDI M, Viswambaram P, McCombie S, Liow E, et al
    (89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma.
    BMJ Open. 2022;12:e060478.
    PubMed    
    Abstract available

  230. FISHER L
    Retraction: Exosome-derived PTENP1 suppresses cisplatin resistance of bladder cancer (BC) by suppressing cell proliferation, migration and inducing apoptosis via the miR-103a/PDCD4 axis.
    RSC Adv. 2021;11:6254.
    PubMed    
    Abstract available

  231. MIYAKE M, Nishimura N, Ohnishi S, Oda Y, et al
    Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer.
    Support Care Cancer. 2022 Apr 14. pii: 10.1007/s00520-022-07043.
    PubMed    
    Abstract available

  232. LIU Q, Wang Y, Gao H, Sun F, et al
    An Individualized Prognostic Signature for Clinically Predicting the Survival of Patients With Bladder Cancer.
    Front Genet. 2022;13:837301.
    PubMed    
    Abstract available

  233. ZHAO Y, Che J, Tian A, Zhang G, et al
    PBX1 Participates in Estrogen-Mediated Bladder Cancer Progression and Chemo-Resistance Affecting Estrogen Receptors.
    Curr Cancer Drug Targets. 2022 Apr 13. pii: CCDT-EPUB-122508.
    PubMed    
    Abstract available

  234. ZHANG Y, Liu Z, Wang X, Jian H, et al
    SHMT2 promotes cell viability and inhibits ROS-dependent, mitochondrial-mediated apoptosis via the intrinsic signaling pathway in bladder cancer cells.
    Cancer Gene Ther. 2022 Apr 14. pii: 10.1038/s41417-022-00470.
    PubMed    
    Abstract available

  235. SINGH YP, Roy D, Jois B, Shetti M, et al
    Reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin for papillary carcinoma of bladder.
    BMJ Case Rep. 2022;15.
    PubMed    
    Abstract available

  236. FUKATA S, Mizutani K, Yamamoto S, Kuno T, et al
    Sarcopenia and the rate of change of the neutrophil/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma.
    Anticancer Drugs. 2022;33:459-466.
    PubMed    
    Abstract available

  237. LEWICKI P, Basourakos SP, Arenas-Gallo C, Qiu Y, et al
    Use of Intravesical Chemotherapy in the US Following Publication of a Randomized Clinical Trial.
    JAMA Netw Open. 2022;5:e220602.
    PubMed    


  238. SHVERO A, Hubosky SG
    Management of Upper Tract Urothelial Carcinoma.
    Curr Oncol Rep. 2022;24:611-619.
    PubMed    
    Abstract available

  239. KUMAR D, Adeniran AJ
    Clinicopathological Review of Micropapillary Urothelial Carcinoma.
    Curr Oncol Rep. 2022;24:603-610.
    PubMed    
    Abstract available

  240. MASTERS JC, Khandelwal A, di Pietro A, Dai H, et al
    Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.
    CPT Pharmacometrics Syst Pharmacol. 2022;11:458-468.
    PubMed    
    Abstract available

  241. HE L, Wang X, Li C, Wan Y, et al
    Bibliometric analysis of the 100 top-cited articles on immunotherapy of urological cancer.
    Hum Vaccin Immunother. 2022;18:2035552.
    PubMed    
    Abstract available

  242. CALDERON CORTEZ JF, Territo A, Fontana M, Gaya JM, et al
    Primary urethral carcinoma: Results from a single center experience.
    Actas Urol Esp (Engl Ed). 2022;46:70-77.
    PubMed    
    Abstract available

  243. NISHIMORI T, Hanazono K, Matsuda K, Kawamura Y, et al
    Prognostic role of DeltaNp63 expression in canine transitional cell carcinoma of the urinary bladder.
    Open Vet J. 2021;11:700-706.
    PubMed    
    Abstract available

  244. GOVONI VM, Pigoli C, Sueiro FAR, Zuliani F, et al
    Lymphatic invasion is a significant indicator of poor patient outcome in canine bladder urothelial carcinoma.
    Open Vet J. 2021;11:535-543.
    PubMed    
    Abstract available

  245. CARRIL-AJURIA L, Martin-Soberon MC, de Velasco G, Agarwal N, et al
    Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review.
    J Cancer Res Clin Oncol. 2022;148:1097-1105.
    PubMed    
    Abstract available

  246. RANTI D, Pfail J, Garcia M, Razdan S, et al
    Neobladder creation in patients with chronic kidney disease: A viable diversion strategy.
    Urol Oncol. 2022;40:168.
    PubMed    
    Abstract available

  247. VENKAT S, Khan AI, Lewicki PJ, Borregales L, et al
    Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma.
    Urol Oncol. 2022;40:108.
    PubMed    
    Abstract available

  248. LI Z, Zhang Z, Ma H, Yao K, et al
    Extraperitonealization of ileal conduit reduces parastomal hernia after cystectomy and ileal conduit diversion.
    Urol Oncol. 2022;40:162.
    PubMed    
    Abstract available

  249. PIERCONTI F, Martini M, Cenci T, Fiorentino V, et al
    The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.
    Urol Oncol. 2022;40:108.
    PubMed    
    Abstract available

  250. CLAIBORNE RT, Tsan GL
    Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
    Optom Vis Sci. 2022;99:88-92.
    PubMed    
    Abstract available

  251. WOO S, Ghafoor S, Das JP, Gangai N, et al
    Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival.
    Urol Oncol. 2022;40:108.
    PubMed    
    Abstract available

  252. YANG CH, Weng WC, Ou YC, Lin YS, et al
    Diffusive Ki67 and vimentin are associated with worse recurrence-free survival of upper tract urothelial carcinoma: A retrospective cohort study from bench to bedside.
    Urol Oncol. 2022;40:109.
    PubMed    
    Abstract available

  253. BUBE SH, Kingo PS, Madsen MG, Vasquez JL, et al
    Validation of a Novel Assessment Tool Identifying Proficiency in Transurethral Bladder Tumor Resection: The OSATURBS Assessment Tool.
    J Endourol. 2022;36:572-579.
    PubMed    
    Abstract available

  254. CHEN X, Ou Z, Wang L, Zhang Z, et al
    Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma.
    Mol Carcinog. 2022;61:311-321.
    PubMed    
    Abstract available

  255. LYON TD, Faraj KS, Brennan E, Tyson MD 2nd, et al
    Defining radical cystectomy using the ICD-10 procedure coding system.
    Urol Oncol. 2022;40:165.
    PubMed    
    Abstract available

  256. SARI MOTLAGH R, Rajwa P, Mori K, Laukhtina E, et al
    Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy So
    J Endourol. 2022;36:535-547.
    PubMed    
    Abstract available

  257. FLAMMIA RS, Chierigo F, Wurnschimmel C, Horlemann B, et al
    Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma.
    Urol Oncol. 2022;40:165.
    PubMed    
    Abstract available

  258. PARK CK, Cho NH
    Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
    Urol Oncol. 2022;40:109.
    PubMed    
    Abstract available

  259. KEENAN RA, Haroon U, Ryan P, Harrington B, et al
    Management of Urological Malignancy in Heart and Lung Transplant Recipients: An Irish National Cohort Study.
    Exp Clin Transplant. 2021;19:1069-1075.
    PubMed    
    Abstract available

  260. AYDIN AM, Reich RR, Cao B, Cheriyan SK, et al
    Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy.
    Urol Oncol. 2022;40:164.
    PubMed    
    Abstract available

  261. YU A, Wang Y, Mossanen M, Preston M, et al
    Robotic-assisted radical cystectomy is associated with lower perioperative mortality in octogenarians.
    Urol Oncol. 2022;40:163.
    PubMed    
    Abstract available

  262. ALBISINNI S, Diamand R, Mjaess G, Assenmacher G, et al
    Continuing acetylsalicylic acid during Robotic-Assisted Radical Cystectomy with intracorporeal urinary diversion does not increase hemorrhagic complications: results from a large multicentric cohort.
    Urol Oncol. 2022;40:163.
    PubMed    
    Abstract available

  263. IAKYMENKO OA, Briski LM, Delma KS, Jorda M, et al
    Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34betaE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
    Am J Surg Pathol. 2022;46:454-463.
    PubMed    
    Abstract available

  264. ALKAN S, Evlice O, Agin A
    The Evaluation of Cases with Ocular Complications due to Bacillus Calmette-Guerin (BCG) Treatment using the Pool Analysis Method.
    Semin Ophthalmol. 2022;37:373-378.
    PubMed    
    Abstract available

  265. TAOKA R, Kobayashi T, Hidaka Y, Abe H, et al
    Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
    Urol Oncol. 2022;40:107.
    PubMed    
    Abstract available

  266. SHIGETA K, Matsumoto K, Ogihara K, Murakami T, et al
    Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
    Urol Oncol. 2022;40:105.
    PubMed    
    Abstract available

  267. CHAKIRYAN NH, Jiang DD, Gillis KA, Green E, et al
    Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder.
    Urol Oncol. 2022;40:107.
    PubMed    
    Abstract available

  268. BHAMIDIPATY M, Rickard MJFX
    An ileal conduit retroperitoneal-pexy: An novel operative technique to treat the rare colonic internal hernia.
    ANZ J Surg. 2022;92:586-587.
    PubMed    


  269. NOJIMA S, Terayama K, Shimoura S, Hijiki S, et al
    A deep learning system to diagnose the malignant potential of urothelial carcinoma cells in cytology specimens.
    Cancer Cytopathol. 2021;129:984-995.
    PubMed    
    Abstract available

  270. COLLA RUVOLO C, Wurnschimmel C, Wenzel M, Nocera L, et al
    Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder.
    J Clin Pathol. 2022;75:333-337.
    PubMed    
    Abstract available

  271. GUO B, Liu M
    The role of chemotherapy in patients with pure squamous cell bladder carcinoma.
    World J Urol. 2022;40:865-866.
    PubMed    


  272. MITCHELL KA, Williams H
    Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes.
    Urol Oncol. 2022;40:126-132.
    PubMed    
    Abstract available

  273. ALMASSI N, Vertosick EA, Sjoberg DD, Wong NC, et al
    Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy.
    BJU Int. 2022;129:463-469.
    PubMed    
    Abstract available

  274. SCHUETTFORT VM, D'Andrea D, Quhal F, Mostafaei H, et al
    A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.
    BJU Int. 2022;129:182-193.
    PubMed    
    Abstract available

  275. LEUNBACH TL, Stilling C, Tabor MB, Bjerggaard Jensen J, et al
    Caveats in the diagnosis of suspected non-endemic verrucous carcinoma in the urinary bladder.
    BJU Int. 2022;129:457-459.
    PubMed    


  276. SUBIELA JD, Rodriguez Faba O, Aumatell J, Calderon J, et al
    Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guerin immunotherapy.
    BJU Int. 2022;129:542-550.
    PubMed    
    Abstract available

  277. HASHEM A, Abdellutif MM, Laymon M, Abdullateef M, et al
    Clinical efficacy of mebeverine for persistent nocturnal enuresis after orthotopic W-neobladder.
    BJU Int. 2022;129:387-393.
    PubMed    
    Abstract available

  278. LEBRET T, Pignot G, Colombel M, Guy L, et al
    Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test.
    BJU Int. 2022;129:356-363.
    PubMed    
    Abstract available

  279. LETT L, George M, Slater R, De Lacy Costello B, et al
    Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.
    Br J Cancer. 2022 Mar 29. pii: 10.1038/s41416-022-01785.
    PubMed    
    Abstract available

  280. DE JONG JJ, Valderrama BP, Perera J, Juanpere N, et al
    Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01799.
    PubMed    
    Abstract available

  281. AN M, Zheng H, Huang J, Lin Y, et al
    Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer.
    Cancer Res. 2022 Apr 8. pii: 694333. doi: 10.1158/0008-5472.CAN-21-4349.
    PubMed    
    Abstract available

  282. CHU CE, Sjostrom M, Egusa EA, Gibb EA, et al
    Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
    Clin Cancer Res. 2021;27:5123-5130.
    PubMed    
    Abstract available

  283. KOUTROS S, Rao N, Moore LE, Nickerson ML, et al
    Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.
    Clin Cancer Res. 2021;27:3725-3733.
    PubMed    
    Abstract available

  284. WANG L, Sfakianos JP, Beaumont KG, Akturk G, et al
    Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
    Clin Cancer Res. 2021;27:4287-4300.
    PubMed    
    Abstract available

  285. GIRARDI DM, Niglio SA, Mortazavi A, Nadal R, et al
    Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
    Clin Cancer Res. 2022;28:1353-1362.
    PubMed    
    Abstract available

  286. SONPAVDE GP, Sternberg CN, Loriot Y, Marabelle A, et al
    Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
    Eur J Cancer. 2022;163:55-65.
    PubMed    
    Abstract available

  287. MAYR R, Eckstein M, Wirtz RM, Santiago-Walker A, et al
    Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guerin Immunotherapy.
    Eur Urol. 2022 Mar 26. pii: S0302-2838(22)01670.
    PubMed    
    Abstract available

  288. ALFRED WITJES J
    Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01786.
    PubMed    


  289. ERTL IE, Lemberger U, Ilijazi D, Hassler MR, et al
    Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.
    Eur Urol. 2022 Apr 4. pii: S0302-2838(22)01678.
    PubMed    
    Abstract available

  290. MCGREGOR B, O'Donnell PH, Balar A, Petrylak D, et al
    Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
    Eur Urol. 2022;81:515-522.
    PubMed    
    Abstract available

  291. GALLIOLI A, Breda A, Palou J
    Re: Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
    Eur Urol. 2022;81:428-429.
    PubMed    


  292. GEAVLETE P, Multescu R, Geavlete B
    Re: How to Manage Patients with Suspected Upper Tract Urothelial Carcinoma in the Pandemic of COVID-19?
    Eur Urol. 2022;81:543.
    PubMed    


  293. NAKAUMA-GONZALEZ JA, Rijnders M, van Riet J, van der Heijden MS, et al
    Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Eur Urol. 2022;81:331-336.
    PubMed    
    Abstract available

  294. HENSLEY PJ, Kamat AM
    Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:316-317.
    PubMed    


  295. RUTKA JT, Fleshner N, Nathens AB
    Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Euro Urol 2021;80:442-9.
    Eur Urol. 2022;81:e51.
    PubMed    


  296. SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
    Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:523-532.
    PubMed    
    Abstract available

  297. CARMEN MIR M, Greenwell T, O'Kelly F, Proietti S, et al
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
    Eur Urol. 2022;81:e26-e27.
    PubMed    


  298. CATHOMAS R, Lorch A, Bruins HM, Comperat EM, et al
    The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
    Eur Urol. 2022;81:95-103.
    PubMed    
    Abstract available

  299. SAAD S, Osman NI, Chapple CR
    Reply to Sanjay B. Kulkarni, Pankaj M. Joshi, Marco Bandini, et al.'s Letter to the Editor re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? Eur Urol 2020;78:e218-9.
    Eur Urol. 2022;81:e16-e17.
    PubMed    


  300. LIEDBERG F, Abrahamsson J, Bobjer J
    Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/
    Eur Urol. 2022;81:e18-e19.
    PubMed    


  301. SHIGETA K, Matsumoto K, Oya M
    Reply to Fredrik Liedberg, Johan Abrahamsson, and Johannes Bobjer's Letter to the Editor re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy have Therapeutic Benefit for Node-positive Upper Tract Urothelial
    Eur Urol. 2022;81:e20-e21.
    PubMed    


  302. DEV S
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
    Eur Urol. 2022;81:e25.
    PubMed    


  303. CLEMENTS MB, Atkinson TM, Dalbagni GM, Li Y, et al
    Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort.
    Eur Urol. 2022;81:294-304.
    PubMed    
    Abstract available

  304. NASELLI A, Pirola GM
    Editorial Comment from Dr Naselli and Dr Pirola to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Mar 31. doi: 10.1111/iju.14883.
    PubMed    


  305. TELLINI R, Mari A, Minervini A
    Editorial Comment from Dr Tellini et al. to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Apr 5. doi: 10.1111/iju.14895.
    PubMed    


  306. HAYAKAWA N, Kikuchi E
    Editorial Comment from Dr Hayakawa and Dr Kikuchi to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Apr 2. doi: 10.1111/iju.14888.
    PubMed    


  307. MIYAKE M
    Editorial Comment to Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
    Int J Urol. 2022;29:364-365.
    PubMed    


  308. OZAKI K, Hatakeyama S, Hamaya T, Okita K, et al
    Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
    Int J Urol. 2022;29:362-364.
    PubMed    


  309. KAWADA T
    Serum irisin concentration in patients with bladder cancer.
    Int Urol Nephrol. 2022 Apr 1. pii: 10.1007/s11255-022-03199.
    PubMed    


  310. SONPAVDE GP, Mouw KW, Mossanen M
    Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.
    J Clin Oncol. 2022;40:1275-1280.
    PubMed    
    Abstract available


  311. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2022;207:1166.
    PubMed    


  312. MASTROIANNI R, Ferriero M, Tuderti G, Anceschi U, et al
    Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.
    J Urol. 2022;207:982-992.
    PubMed    
    Abstract available

  313. ROLLIN P, Xylinas E, Lanz C, Audenet F, et al
    [Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie].
    Prog Urol. 2022;32:326-331.
    PubMed    
    Abstract available

  314. WU Z, Xia C, Zhang C, Yang D, et al
    Prognostic significance of SNCA and its methylation in bladder cancer.
    BMC Cancer. 2022;22:330.
    PubMed    
    Abstract available

  315. FANG C, Huang X, Dai J, He W, et al
    The circular RNA circFARSA sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.
    BMC Cancer. 2022;22:373.
    PubMed    
    Abstract available

  316. ISONO M, Okubo K, Asano T, Sato A, et al
    Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
    PLoS One. 2022;17:e0266476.
    PubMed    
    Abstract available

  317. KANG DH, Cho KS, Moon YJ, Chung DY, et al
    Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation.
    PLoS One. 2022;17:e0267410.
    PubMed    
    Abstract available

  318. SUN X, Xie L, Qiu S, Li H, et al
    Elucidation of CKAP4-remodeled cell mechanics in driving metastasis of bladder cancer through aptamer-based target discovery.
    Proc Natl Acad Sci U S A. 2022;119:e2110500119.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;